Our findings underscore the potential of combining CD19-targeted immunotherapy with CXCR4 antagonists to overcome the resistance mechanisms often associated with CXCL12–CXCR4 signaling in lymphoma cells [15,16,43]. Here, CD19 is linked to lymphoma.